Halozyme Therapeutics: Q2 Earnings Insights - Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics HALO reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.

Here's what investors need to know about the announcement.

Halozyme Therapeutics beat estimated earnings by 6.0%, reporting an EPS of $0.53 versus an estimate of $0.5.

Revenue was up $15.91 million from the same period last year.

Last quarter the company missed on EPS by $0.02 which was followed by a 0.99% increase in the share price the next day.

Here's a look at Halozyme Therapeutics's past performance:

Quarter	Q1 2022	Q4 2021	Q3 2021	Q2 2021
EPS Estimate	0.49	0.41	0.42	0.40
EPS Actual	0.47	0.42	0.55	0.66
Revenue Estimate	128.25M	100.32M	101.94M	103.16M
Revenue Actual	117.28M	102.00M	115.83M	136.46M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Halozyme Therapeutics management provided guidance for FY 2022, expecting earnings between $2.1 and $2.25 per share.

To track all earnings releases for Halozyme Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.